271 related articles for article (PubMed ID: 27653425)
1. Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
Tyson MD; Graves AJ; O'Neil B; Barocas DA; Chang SS; Penson DF; Resnick MJ
JAMA Surg; 2017 Jan; 152(1):27-34. PubMed ID: 27653425
[TBL] [Abstract][Full Text] [Related]
2. Physician variation in management of low-risk prostate cancer: a population-based cohort study.
Hoffman KE; Niu J; Shen Y; Jiang J; Davis JW; Kim J; Kuban DA; Perkins GH; Shah JB; Smith GL; Volk RJ; Buchholz TA; Giordano SH; Smith BD
JAMA Intern Med; 2014 Sep; 174(9):1450-9. PubMed ID: 25023650
[TBL] [Abstract][Full Text] [Related]
3. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US.
Washington SL; Jeong CW; Lonergan PE; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
JAMA Netw Open; 2020 Dec; 3(12):e2031349. PubMed ID: 33369661
[TBL] [Abstract][Full Text] [Related]
4. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer.
Filson CP; Schroeck FR; Ye Z; Wei JT; Hollenbeck BK; Miller DC
J Urol; 2014 Jul; 192(1):75-80. PubMed ID: 24518783
[TBL] [Abstract][Full Text] [Related]
5. Racial disparities in changing to a high-volume urologist among men with localized prostate cancer.
Pollack CE; Bekelman JE; Epstein AJ; Liao K; Wong YN; Armstrong K
Med Care; 2011 Nov; 49(11):999-1006. PubMed ID: 22005606
[TBL] [Abstract][Full Text] [Related]
6. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
7. Physician social networks and variation in prostate cancer treatment in three cities.
Pollack CE; Weissman G; Bekelman J; Liao K; Armstrong K
Health Serv Res; 2012 Feb; 47(1 Pt 2):380-403. PubMed ID: 22092259
[TBL] [Abstract][Full Text] [Related]
8. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
J Natl Cancer Inst; 2006 Jun; 98(12):839-45. PubMed ID: 16788157
[TBL] [Abstract][Full Text] [Related]
9. Urologist Practice Structure and Spending for Prostate Cancer Care.
Modi PK; Herrel LA; Kaufman SR; Yan P; Borza T; Skolarus TA; Schroeck FR; Hollenbeck BK; Shahinian VB
Urology; 2019 Aug; 130():65-71. PubMed ID: 31029672
[TBL] [Abstract][Full Text] [Related]
10. Physician visits prior to treatment for clinically localized prostate cancer.
Jang TL; Bekelman JE; Liu Y; Bach PB; Basch EM; Elkin EB; Zelefsky MJ; Scardino PT; Begg CB; Schrag D
Arch Intern Med; 2010 Mar; 170(5):440-50. PubMed ID: 20212180
[TBL] [Abstract][Full Text] [Related]
11. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
12. The Influence of Practice Structure on Urologists' Treatment of Men With Low-Risk Prostate Cancer.
Mitchell JM; Gresenz CR
Med Care; 2022 Sep; 60(9):665-672. PubMed ID: 35880758
[TBL] [Abstract][Full Text] [Related]
13. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer.
Fowler FJ; McNaughton Collins M; Albertsen PC; Zietman A; Elliott DB; Barry MJ
JAMA; 2000 Jun; 283(24):3217-22. PubMed ID: 10866869
[TBL] [Abstract][Full Text] [Related]
14. Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign.
Makarov DV; Soulos PR; Gold HT; Yu JB; Sen S; Ross JS; Gross CP
JAMA Oncol; 2015 May; 1(2):185-94. PubMed ID: 26181021
[TBL] [Abstract][Full Text] [Related]
15. Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF
BMC Urol; 2015 Apr; 15():25. PubMed ID: 25885745
[TBL] [Abstract][Full Text] [Related]
16. Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
Kim SP; Gross CP; Nguyen PL; Smaldone MC; Shah ND; Karnes RJ; Thompson RH; Han LC; Yu JB; Trinh QD; Ziegenfuss JY; Sun M; Tilburt JC
Med Care; 2014 Jul; 52(7):579-85. PubMed ID: 24926704
[TBL] [Abstract][Full Text] [Related]
17. The Development and Validation of Prostate Cancer-specific Physician-Hospital Networks.
Jacobs BL; Yabes JG; Lopa SH; Heron DE; Chang CH; Bekelman JE; Nelson JB; Bynum JPW; Barnato AE; Kahn JM
Urology; 2020 Apr; 138():37-44. PubMed ID: 31945379
[TBL] [Abstract][Full Text] [Related]
18. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
[TBL] [Abstract][Full Text] [Related]
19. Expectant management of veterans with early-stage prostate cancer.
Filson CP; Shelton JB; Tan HJ; Kwan L; Skolarus TA; Saigal CS; Litwin MS
Cancer; 2016 Feb; 122(4):626-33. PubMed ID: 26540451
[TBL] [Abstract][Full Text] [Related]
20. Which Patients Report That Their Urologists Advised Them to Forgo Initial Treatment for Prostate Cancer?
Radhakrishnan A; Grande D; Mitra N; Pollack CE
Urology; 2018 May; 115():133-138. PubMed ID: 29477313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
